Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 3/20 | 0.47 |
| ▸ | WNT3A | P56704 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ASPH | Q12797 | 1/20 | 0.43 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL27789252 | 0.97 | CTNNB1 (0.45) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL25413317 | 0.93 | CTNNB1 (0.47) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL29949958 | 0.81 | ROCK2 (0.49) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL4144213 | 0.81 | TSHR (0.47) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL1600048 | 0.81 | CTNNB1 (0.47) | CTNNB1WNT3ANPC1RAB9AROCK1 | |
| SCHEMBL11261159 | 0.79 | CHEK1 (0.61) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL23149316 | 0.79 | FABP3 (0.49) | CTNNB1WNT3ANPC1RAB9AHPGD | |
| SCHEMBL27817106 | 0.77 | CASP6 (0.50) | CTNNB1WNT3ANPC1RAB9AROCK1 | |
| SCHEMBL14738406 | 0.77 | CHEK1 (0.56) | RAB9AHPGDROCK1ROCK2KDM4E | |
| SCHEMBL25247945 | 0.76 | CHEK1 (0.61) | CTNNB1WNT3ANPC1RAB9AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-1809282-B1 | THIADIAZOLE COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7919514-B2 | Protein kinase B inhibitors; anticarcinogenic, antiinflammatory and antiproliferative agents; metabolic disorders; 3-(3-fluoro-phenyl)-N-[5-(3-methyl-1H-indazol-5-yl)-[1,3,4]thiadiazol-2-yl]-propane-1,2-diamine and derivatives | AMGEN INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7700636-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2010-04-20 | — | — | US | disclosed |
| CN-101389335-A | Thiadiazole compounds and methods of use. | AMGEN INC (US) | 2009-03-18 | — | — | CN | disclosed |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255145-A1 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7354944-B2 | Thiadiazole compounds and methods of use | AMGEN INC. (US) | 2008-04-08 | — | — | US | disclosed |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | AMGEN INC. | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255145-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | CTNNB1 1576/4885WNT3A 2110/4885NPC1 2069/4885 |
| US-20080269243-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | CTNNB1 1576/4885WNT3A 2110/4885NPC1 2069/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | CTNNB1 4388/4885WNT3A 4626/4885NPC1 2025/4885 |
| US-20060154961-A1 | Thiadiazole compounds and methods of use | PDK2, PDK1, PANK2 | CTNNB1 1576/4885WNT3A 2110/4885NPC1 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.